2024 年 10 月 – 第 7 頁 – Today in Hong Kong

ACN Newswire

Governments, Law Enforcement, and Industry Leaders to Convene at Global Anti-Scam Summit Americas 2024 in Washington D.C.

10/25/2024

Washington, D.C., Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Online scams wreak havoc across the Americas and globally, causing significant financial and emotional damage. The Global Anti-Scam Summit (GASS) Americas 2024, organized by the Global Anti-Scam Alliance (GASA) and hosted by Amazon.com, Inc., aims to combat these growing threats. The summit will feature over 30 hours of presentations, workshops, and interactive sessions across ten critical tracks, all focused on developing a global defense strategy to protect consumers and inform regulation.The summit will empower experts to take decisive action by focusing on the impact on victims, highlighting global scam statistics, explaining emerging scam tactics, and fostering international cooperation. The aim is to provide a roadmap for regulatory bodies to drive meaningful change.With $1.026 billion in global scam losses in 2023, this event seeks to mitigate further damage in 2024 and beyond.Day 1 will address the human and policy aspects of scams:Victim Impact: Led by AARP, this session delves into the emotional and financial toll on victims and their communities.Policy: The Aspen Institute will explore regulatory gaps and legislative solutions, sharing best practices from around the world.Law Enforcement: Chaired by UNODC, this session focuses on the collaboration between local and international agencies to disrupt scam networks.Data & Signal Sharing: GASA and DNS Research Federation will unveil plans for an international cybercrime exchange to reduce cybercrime by 50% in 10 years.Bank Collaboration: This session, led by Feedzai, will explore the critical role of banks in preventing scams.Day 2 will shift to specific industries and technologies most at risk:Financial Services: Featuring industry leaders like Capital One and Mastercard, this session will explore how multi-sector collaboration can build the perfect anti-fraud infrastructure.Telecom: Focuses on how telecom companies can improve security to protect consumers.Customer Digital Experience: Major platforms like Amazon will discuss how to strengthen protections at key digital touchpoints.Blockchain: Investigating scams in crypto and blockchain, chaired by Cube3.AI.Cybersecurity: Trend Micro will lead panels on advanced investigation techniques, focusing on scams like sextortion and pig butchering.Uniting Expertise for a Scam-Free Future"Consumers globally are facing a crisis with scams. Governments, private industry, and law enforcement must come together and act now," says Jorij Abraham, Managing Director of GASA. "Our aim at this summit is not only to discuss the problems but to build solutions that protect consumers worldwide."Confirmed Speakers:Glen Prichard, UNODCJean-Jacques Sahel, GoogleMatthew Noyes, U.S. Secret ServiceLaura Quevedo, MastercardBen Chance, ZelleAmy Nofziger, AARPMauro Ellovitch, MPMGThe summit will also launch the annual Global State of Scams Report 2024, offering an in-depth analysis of major scam trends and their impact.Join us in Washington, D.C., for this landmark event. Visit gasa.org/gass-2024-americas to view the full schedule and register.Contact InformationSam RogersMarketing Director, Global Anti-Scam Alliancesam.rogers@gasa.orgSOURCE: Global Anti-Scam Alliance (GASA) Copyright 2024 ACN Newswire via SeaPRwire.com.

ACN Newswire

Vyasa Yoga SG Marks Silver Jubilee with International Wellness Conference

10/25/2024

SINGAPORE, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Vyasa Yoga SG, Singapore’s leading yoga institute, proudly celebrated its Silver Jubilee this month, marking 25 years of transforming lives through yoga and holistic health practices. Founded with S-VYASA, Vyasa Yoga SG has empowered thousands through its scientific, research-based yoga training and therapy programs, building a community of 3,000 certified yoga instructors and 500 yogi health therapists.The Silver Jubilee celebrations were inaugurated by esteemed guests, including Deputy High Commissioner of India Pooja Tillu, Neil Parekh, Chairman of Singapore Indian Chamber of Commerce and Industry (SICCI), Dr. H R Nagendra Guruji, Padma Shri awardee and renowned yoga guru, and Dr. Manjunath NK, Vice-President of the Asian Yoga Therapy Association, alongside Vyasa Yoga SG Founder, Manoj Thakur.To commemorate the milestone, Vyasa Yoga SG hosted the **International Conference on "Comprehensive Wellness Strategy" from October 19th to 20th, 2024 at the Galaxy Ballroom, CSC Tessensohn Club. The conference brought together 50 experts from 11 countries to explore integrating ancient yoga wisdom with modern science to enhance well-being. In her keynote address, Deputy High Commissioner Pooja Tillu emphasized the global relevance of yoga, stating: “Continue embracing yoga practice as a guiding light that will bring us together as a global family.”Manoj Thakur, Founder of Vyasa Yoga SG, reflected on the institute’s journey, “It has been a remarkable 25-year journey. Our success reflects the spirit of well-being we have cultivated in Singapore and beyond. We look forward to guiding people towards healthier, happier lives for many more years to come.”The event featured live yoga demonstrations and a special recognition ceremony to honor the institute’s significant contributions to health and wellness in Singapore. Vyasa Yoga SG is planning a series of events throughout the year to celebrate its 25th anniversary.About Vyasa Yoga SGEstablished to promote a healthy lifestyle through a scientific approach to yoga, Vyasa Yoga SG offers a variety of accredited programs for all ages and levels. With a mission to foster a culture of well-being, the institute continues to be at the forefront of holistic health in Singapore. For more information, visit https://vyasasingapore.com/. For further media queries contact:Ganesh Somwanshiganesh@mettai.world Copyright 2024 ACN Newswire via SeaPRwire.com.

Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area

10/25/2024

SHANGHAI, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. Subsequently, VELSIPITY(R) will be introduced in other qualified hospitals under the connect policy. VELSIPITY(R) is now the third commercialized product of Everest Medicines.VELSIPITY(R) is an innovative advanced therapy that was officially approved by the Pharmaceutical Administration Bureau of Macau in April 2024. It is an oral treatment taken once daily for the treatment of patients aged 16 and above with moderately to severely active UC. UC is a chronic, relapsing, non-specific inflammatory disease, and as the disease progresses, the risk of disability and colorectal cancer incidence continues to rise. By 2030, the number of patients with UC in China is expected to more than double compared to 2019, reaching approximately 1 million, with a significant unmet need for innovative therapies.“The launch of VELSIPITY(R) in the Greater Bay Area accelerates the access to this advanced therapy in mainland China, offering a new option for patients with moderately to severely active UC." Said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Everest Medicines is committed to expeditiously delivering innovative therapies to patients. Moving forward, we will keep leveraging our strengths and exploring innovative ways to improve the accessibility of these therapies. We plan to have VELSIPITY(R) submitted for new drug application in mainland China by the end of this year, further enhancing its accessibility and benefiting more patients." VELSIPITY(R) was developed by Arena Pharmaceuticals, which was acquired by Pfizer in 2022. Everest Medicines obtained exclusive rights to develop, produce, and commercialize VELSIPITY(R) in Greater China and South Korea from Arena as early as 2017. As a core product in the field of autoimmune diseases for Everest Medicines, VELSIPITY(R) was successively approved in Macau and Singapore in the first half of this year and was approved in the United States and the European Union in October last year and February this year, respectively. In addition, Everest Medicines recently submitted an new drug application for VELSIPITY(R) in Hong Kong, China.VELSIPITY(R) is the first and only advanced oral UC therapy approved for use in patients 16 years of age or older in the EU, and the ELEVATE UC 52 and ELEVATE UC 12 were the only studies of advanced therapies for UC to include patients with isolated proctitis. In the results of the Asian multi-center Phase 3 clinical trial of VELSIPITY(R) for the treatment of moderately to severely active UC announced in July this year, VELSIPITY(R) achieved positive topline data results in both the induction and maintenance treatment periods, with good safety profile, and is convenient to take once a day, providing further solid scientific basis and support for the wide application of the drug in clinical practice.About VELSIPITY(R) (etrasimod)VELSIPITY(R) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau for VELSIPITY(R) in ulcerative colitis.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.

Finance

Hachiko 宣布推出：最新狗狗迷因幣，以忠誠的傳奇和勢不可擋的成長

10/25/2024

(SeaPRwire) - 日本最著名且最具传奇色彩的狗狗。日本东京，2024 年 10 月 24 日 -- 在狗狗币兴起又消逝的世界中，Hachiko 作为忠诚、力量和根深蒂固的历史象征而脱颖而出。Hachiko 受到以其坚定的忠诚而闻名的传奇日本犬的启发，不仅仅是另一种狗狗币——它是一个建立在信任、社区和长期愿景价值观基础上的运动。随着加密货币市场持续发展，Hachiko 有望成为下一个大型狗狗币，其强大的叙事吸引着来自世界各地的持有者。源于忠诚的遗产 Hachiko 不仅仅是任何狗狗币。它源于 Hachiko 的真实故事，这只忠诚的秋田犬在主人去世后近十年每天都在东京涩谷车站等待他的主人。这个感人的忠诚故事已铭刻在日本历史上，现在成为一个旨在重新定义加密货币世界中忠诚度的项目的基石。与 Hachiko 从不动摇的方式相同，该项目旨在经受住市场起伏，提供以社区为中心的体验，奖励那些相信长期增长和共同成功的人。为什么 Hachiko 有望实现爆炸式增长 Hachiko 项目触及了 Shiba Inu 和 Dogecoin 等币种取得巨大成功背后的核心——社区和讲故事。但与其他狗狗币不同的是，Hachiko 拥有不可否认的历史叙事，引起了深刻的共鸣。这不仅仅是另一个追逐炒作的代币；它是一个有目的、有激情且对未来有清晰愿景的项目。 Hachiko 強大的叙事和项目致力于社区的结合，为指数级增长奠定了基础。Hachiko 已经开始在 CoinGecko 等加密货币交易所和上市平台上获得关注，其忠实的持有者对接下来会发生的事情感到兴奋。随着即将到来的路线图中包含新的功能、合作伙伴关系和社区奖励，现在加入 Hachiko 运动从未如此好。社区的力量：#LoyalLikeHachiko Hachiko 成功的核心是其社区。#LoyalLikeHachiko 运动不仅仅是一个口号——它是一种生活方式，对于那些相信在市场波动期间团结一致的力量的人来说。Hachiko 已经经受住了从 FUD 到市场调整的挑战，但其忠实的持有者一次又一次地证明了他们的承诺。这种坚定不移的忠诚反映了 Hachiko 本人的故事，并使社区更加强大。 Hachiko 不仅仅是在构建一个代币——它是在创造一种遗产。无论你的背景或加密经验如何，每个人都可以参与的项目。无论你是经验丰富的投资者还是加密货币新手，Hachiko 都张开双臂欢迎你，提供一个每个人声音都有价值的支持性社区。 Hachiko 的未来：为持久性而建 Hachiko 项目拥有已经开始实施的长期愿景。从即将推出的 NFT 发布到慈善合作伙伴关系，Hachiko 背后的团队正在不懈努力地为其持有者提供真正的价值。该项目致力于透明度和创新，将自己定位为狗狗币领域中的领导者，重点关注可持续性和未来增长。随着 Hachiko 101 周年纪念日即将来临，该项目计划盛大庆祝这一里程碑。你为什么应该加入 Hachiko 运动加密货币市场充满了短期收益和逐渐消失的项目。但 Hachiko 并不关乎快速上涨或短暂的炒作——它关乎建立持久的东西，就像激发其创造的忠诚的狗狗一样。凭借强大的叙事、致力于社区和致力于长期成功的团队，Hachiko 正在迅速成为该领域最激动人心的项目之一。如果你相信忠诚、成长和社区的力量，Hachiko 就是适合你的项目。现在是加入这个非凡运动并帮助撰写 Hachiko 传奇故事的下一章的时候了。关注 Hachiko 的社交媒体，以了解更多关于该项目的信息！网站： Telegram： Twitter X： Coinmarketcap：免责声明：本新闻稿中提供的信息并非投资招揽，也不构成投资建议、财务建议或交易建议。强烈建议您在投资或交易加密货币和证券之前进行尽职调查，包括咨询专业的财务顾问。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。联系方式：Akiko Tanaka Info (at) hachiko-token.com

君聯投資企業地平線在香港聯交所成功上市

10/25/2024

香港, 2024年10月25日 - (亞太商訊 via SeaPRwire.com) - 據君聯資本微信公號報道稱，10月24日，聯想控股（3396.HK）旗下君聯資本所投智駕科技企業地平線（9660.HK）在香港聯交所成功上市，地平線擬全球發行1,355,106,600股股份，其中香港公開發售135,511,200股，佔約10%；國際配售1,219,595,400股，佔約90%，另有超額配股權15%。截至發稿，地平線每股5.45港元，上市首日上漲36.59%，市值超過710億港元。這標誌著地平線作為一家智能駕駛解決方案的鏈主型領軍企業，開啟了全新「征程」。地平線是市場領先的乘用車高級輔助駕駛（ADAS）和高階智能駕駛（AD）解決方案供應商，成立於2015年7月，創始人余凱博士，本碩畢業於南京大學電子科學與工程學系，長期在計算機工程領域深耕。地平線的產品包括征程系列芯片，這些芯片被廣泛應用於智能駕駛領域，包括高級輔助駕駛（ADAS）和高階智能駕駛（AD）解決方案。依託已大規模部署的前裝量產解決方案，地平線已成為智能汽車轉型及商業化的關鍵推動者。灼識咨詢報告顯示，自2021年起，按解決方案總裝機量計算，地平線是首家且每年均為最大的提供前裝量產的高級輔助駕駛和高階智能駕駛解決方案的中國公司。地平線擁有龐大的全球客戶群，包括行業領先的OEM（原始設備製造商）和國產汽車製造一級供應商，公司提供的解決方案整合了算法、專用軟件和處理硬件，旨在提高駕駛安全性和乘客體驗。截至2024年9月底，地平線累計定點車型290款、累計量產車型152款。目前，地平線征程家族車載智能計算方案出貨量累計已突破600萬套。2024年上半年，地平線營業收入9.3億元，同比增長超150%。君聯資本於2021年3月投資地平線，投資時地平線生產的智能駕駛芯片在各車企剛剛開始投入應用，投資後，公司產品持續迭代，研發生產了國內首款可量產的百TOPs級車載大算力智能駕駛芯片——征程5系列產品並形成批量生產應用，公司最新研發的征程6也持續量產並在各大車企銷售。君聯一路陪伴公司成長，在智能駕駛產業鏈上下游資源引薦等方面給予了公司支持和幫助。君聯資本對地平線成功上市表示祝賀，隨著汽車「智能化、網聯化」的驅動，智能駕駛芯片已成為智能汽車智能駕駛的核心，地平線是行業內稀缺的有能力將算力在芯片產品上落地的企業，余凱博士帶領的團隊具有遠大格局和前瞻性，有較強的商業落地能力和豐富的企業管理經驗，隨著我國智能汽車行業的持續增長，君聯資本相信，上市後的地平線在智能駕駛領域將會持續拓展更廣闊的市場和業務鏈條。智能駕駛技術是新質生產力的典型代表。君聯長期實踐科創投資，在人工智能、碳中和、半導體、數字經濟、生物醫藥等國家戰略性產業上密集投資，深入理解和融入國家創新型企業培育體系，持續推動所投企業面向解決「卡脖子」問題的重大創新方向，補鏈強鏈。君聯資本作為聯控旗下專注于早期創業投資以及成長期私募股權投資的專業投資機構，在二十多年的發展歷程中，遵循國際通行標準，經歷了多支基金的完整管理週期，創造了可持續的基金業績。據其官網顯示，已累計投資600多家企業，其中有113家在全球不同資本市場IPO退出，近100家通過並購退出。其所投企業中，既包括科大訊飛、寧德時代、藥明康得、康龍化成這樣的頂尖企業，也有大量的國家級專精特新小巨人和製造業單項冠軍，構建了豐富的產業資源。 Copyright 2024 亞太商訊 via SeaPRwire.com.

僑雄國際否認媒體操縱股價質疑稱價格波動是市場對公司未來預期反應

10/25/2024

香港, 2024年10月25日 - (亞太商訊 via SeaPRwire.com) - 針對公司近日股價持續上漲，引發媒體質疑涉嫌操縱股價的報導、僑雄國際(00381.HK)今日盤後發佈公告稱，經公司董事會作出一切合理查詢後所知、所悉及所信，董事會堅決否認媒體報導中包含的猜測，並認為報導事項不准確且具有誤導性。僑雄國際在公告中進一步指出，公司已經諮詢其法律顧問，將會作出進一步行動。此外公司向負責傳播誤導性及惡意陳述，惡意沽空從而獲益的有關實體及╱或相關個人及任何人，導致的損害或其他補償，保留採取法律行動之權利。10月22日，有媒體發佈題為《16個交易日翻了近30倍，僑雄國際（00381）全靠兩個"經紀商"雄起？》，指出截至10月21日，中國北方證券和長橋證券兩個經紀商近20個交易日分別淨買入了0.92億股和0.27億股，持股比例分別為14.02%及3.42%，而其他經紀商僅有少量買入，由此質疑公司股價存在被操縱的嫌疑。僑雄國際執行董事兼聯席主席李立中對媒體回應稱，價格的波動是市場對公司未來預期的反應，是正常的市場行為。首先，乘著近期港股的升浪，很多公司股票都有明顯的升幅。加上公司近來管理層的變動，委任了有豐富資歷以及管理經驗的董事，這些可被股東看作利好消息，公司股價上漲表示股東對公司前景樂觀。二零二四年十月四日，僑雄國際委任李立中為執行董事兼聯席主席。李立中長期從事人工智慧、元宇宙、智聯網路、區塊鏈科學研究，這些領域的研究成果不僅推動了科技進步，而且為人類的生活帶來了巨大的改變。其工作成果向世界展示了中國科學家的智慧和實力，也為中國在科技領域的發展做出了重要貢獻。僑雄國際表示，國家「十四五」規劃中提出迎接數字時代，啟動數據要素潛能，推進網絡強國建設，加快建設數字經濟、數字社會、數字政府，以數字化轉型整體驅動生產方式、生活方式和治理方式變革。基於「十四五」規劃所帶來的數字化新浪潮，各行各業將獲得更多發展機遇，面對中國社會經濟發展新階段、新特徵，公司未來將專注於深化現有業務開發及運營，向數字媒體經銷等方向穩定發展，豐富業務的多元化結構，使得公司更加穩步向前。僑雄國際在公告中表示，董事會經作出在相關情況下有關公司的合理查詢後，董事會確認，其並不知悉導致價格或成交量波動的任何原因，或任何必須公佈以避免公司證券出現虛假市場的資料。李立中強調，該報導僅憑市場交易券商名字片面的指責懷疑公司操縱市場，期間並未與上市公司做任何的溝通與確認，是典型惡意沽空的犯罪行為。公司會對其新聞前惡意做空行為和新聞後操縱市場行為發出律師函和訴訟，以維護廣大投資者權益。前述媒體報導稱，"僑雄國際基本面並不好，公司主要從事玩具及禮品製造及銷售、天然資源勘探、水果種植、休閒及文化及中草藥多種業務，業務表現平淡，業績收入已經連續兩個半年度下行，且盈利能力持續下降。今年該公司業務模式並未有重大變化，唯一變化是在10月10日，擬將公司名稱更名為權識國際集團（中文名稱）。"僑雄國際近期發佈公告，擬將公司名稱更改為"AOM International Group Company Limited"，並採用"權識國際集團股份有限公司"作為其第二中文名稱。據悉，集團的業務有六大可呈報分類，由於各業務均有不同的經濟特徵，因此各業務被分開管理。對此李立中表示，僑雄國際更名為權識國際。未來會通過相關專利技術對公司各板塊業務做全方位的數位經濟轉型，通過生產資料的標識化，為公司的各個板塊注入新的價值與活力。因此引發股價上漲和投資者購買屬於正常市場現象。李立中指出，目前僑雄國際的資金狀況非常健康，公司管理層對公司發展的前景保持絕對的樂觀態度，會考慮在未來繼續增持公司股票，以帶給市場及公司股東信心，穩定因為不實報道，故意抹黑而影響的公司股價。關於後續的業務安排，公司會按照上市公司管理要求走合規的業務流程正常公告披露。公司謹提醒公司股東及潛在投資者，關注公司於聯交所網站(http://www.hkexnews.hk/index.htm) 。 Copyright 2024 亞太商訊 via SeaPRwire.com.

ACN Newswire

Founder of Hua Medicine Dr. Chen Li was awarded the ‘C.C. Tan Life Science Industrialization Award’

10/25/2024

HONG KONG, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the “C.C. Tan Life Science Industrialization Award”. C.C. Tan Life Science Award has the highest honor as “the Chinese Nobel” in life science. In the context of the comprehensive construction of Chinese-style modernization and the development of new productivity, this award is a high recognition of Dr. Chen Li's outstanding contributions to the industrialization of life science achievements, and a full affirmation of his decades-long efforts to promote conceptual, technological and institutional innovations in biopharmaceutical industry.Dr. Chen Li participated in the award ceremony and received the “C.C. TanLife Science Industrialization Award”.“C.C. Tan Life Science Award” was proposed by Mr. Tan Jiazhen, one of the founders of modern genetics in China and an outstanding scientist and educator in modern China, which was approved by the Ministry of Science and Technology of the People's Republic of China, aims to promote the industrialization of China's life sciences research results and stimulate life scientists to make innovations. Since its establishment in 2008, C.C. Tan Life Science Award has been awarded annually to scientists, professors and young scholars who have made achievements in life science in the People's Republic of China and have made outstanding contributions to the industrialization of scientific and technological achievements in life science.With more than 30 years of experience in new drug R&D and management, Dr. Chen Li returned to Shanghai from the U.S. in 2004, and participated in the establishment of Roche R&D Center, the first R&D center of a multinational company in Shanghai, bringing the advanced experience, talent concept, technical standards and quality management system of international new drug R&D to China, and contributing to the establishment of the environment of China's biopharmaceutical industry. Dr. Chen Li has contributed to the establishment of China's biopharmaceutical industry environment.In 2010, Dr. Chen Li founded Hua Medicine in Zhangjiang, Shanghai, with the original intention of “China leads the way in pharmaceutical innovation”, adhering to the tenet of “patients first, innovation first, and good medicines for the people”, focusing on the unmet clinical needs, and concentrating on the research and development of first-of-its-kind new medicines for diabetes. Dr. Chen Li is not only one of the earliest pioneers to leave his executive position at a multinational pharmaceutical company to start a local innovative drug company, but also a leader in developing First-in-Class drugs in China.In September 2022, under the leadership of Dr. Chen Li, Hua Medicine's world's first, China's first, Class I National New Drug, Dorzagliatin (trade name: HuaTangNing®), which took ten years to develop independently, received marketing approval from the State Food and Drug Administration (SFDA), making it the first Glucose Kinesin Activator (GKA) approved and marketed globally, and the tenth class of diabetes therapeutic drugs.As the world's first GKA drug, Dorzagliatin utilizes the new concept of “repairing sensing, reshaping homeostasis, and treating diabetes at the source” to achieve the improvement of blood glucose homeostasis dysregulation in patients with type 2 diabetes mellitus, and to bring a brand-new treatment for diabetes mellitus patients, which is a major breakthrough in the history of drug research and development of China in the field of major chronic diseases. During the development of Hua Medicine, Dr. Chen Li has actively contributed to the development of China's biopharmaceutical industry. He has provided constructive opinions and suggestions for the system of marketing license holders and the system of patent linkage and patent protection, etc. He has cooperated with enterprises in the industry chain in the R&D and production of dorzagliatin to establish a joint innovation model, which has led to the development of the ecological development of the biopharmaceutical industry. In early 2024, Dr. Chen Li was awarded the first “Shanghai Outstanding Talent”. He is also the inventor of 119 granted invention patents and 270 invention patent applications and has been published more than 70 scientific papers in Nature Medicine, Lancet Diabetes Endocrinology, Nature Communication, PNAS, Diabetes, Obesity Metabolism, and the Journal of Biomedicine. PNAS, Diabetes, Obesity Metabolism, JACS, JOC and other international academic journals.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

ACN Newswire

DIFC continues to drive global action in shaping greener economies – Announces 2nd edition of the Future Sustainability Forum in Dubai

10/25/2024

DUBAI, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Dubai International Financial Centre (DIFC), the leading global financial hub in the Middle East, Africa and South Asia (MEASA) region, announces the 2nd edition of the Future Sustainability Forum. Scheduled for 4 and 5 December 2024 at the Madinat Jumeirah, Dubai, the Forum will focus on mobilising sustainable practices, engaging in influential discussions on sustainable development, working towards environmental conservation, social equity and innovation.The announcement of the 2nd edition of the Forum underscores DIFC’s commitment to advancing UAE sustainability priorities alongside initiatives such as the DIFC Sustainable Finance Catalyst which aims to grow sustainable finance flows from Dubai to USD 100+ billion by 2030.The Forum coincides with the first anniversary of COP28 being hosted in the UAE and is set to attract over 3,000 participants. The event will mobilise industry leaders, investors, tech disruptors, and policymakers into achieving the United Nations Sustainable Development Goals (SDGs) and contributing to the delivery of the Paris Agreement, whilst aiming to channel investment flows between the global north and south to accelerate climate action.Alya Al Zarouni, Chief Operating Officer of DIFC Authority and Co-Chair of the Dubai Sustainable Finance Working Group, said, “The DIFC organised Future Sustainability Forum is a vital platform for collaborative action towards a more sustainable future. As the global economic landscape evolves, so must our commitment to responsible and inclusive growth. At DIFC, we are proud to be convening this gathering of industry leaders, innovators, and policymakers to address the most pressing environmental and social challenges of our time. Together, we can forge new pathways to a more resilient and sustainable future for financial services and other important industries.”Dr Bernd van Linder, Chief Executive Officer of the Commercial Bank of Dubai, the presenting sponsor of the Forum, stated, "Commercial Bank of Dubai is proud to support the UAE's sustainability ambitions through our participation in the Future Sustainability Forum 2024 as Presenting Sponsor. Our proactive approach in addressing environmental challenges, exemplified by the successful issuance of CBD's inaugural green bond, demonstrates our alignment with global environmental goals."The Forum will address critical sustainability issues across eight core pillars spanning different industries including banking and finance, construction, renewable and future energy, transportation and mobility, manufacturing and production, recycling and waste management, sustainable technology, and agriculture and food production.In addition to the packed conference agenda that will feature over 100 sustainability and climate action expert speakers, the Forum will bring together the most innovative solutions and service providers from across the global sustainability landscape through the Climate Action & Renewable Energy Expo (CARE).Government entities in the UAE have spearheaded a range of comprehensive sustainability programmes in the pursuit of a net-zero future. Initiatives such as the Dubai Clean Energy Strategy 2050, the UAE Net Zero 2050 strategic initiative, and the UAE Vision 2070, emphasise on a commitment to renewable energy adoption, water conservation, waste management, and sustainable urban development.For more information and to register, please visit the Future Sustainability Forum website.About Dubai International Financial CentreDubai International Financial Centre (DIFC) is one of the world’s most advanced financial centres, and the leading financial hub for the Middle East, Africa, and South Asia (MEASA), which comprises 77 countries with an approximate population of 3.7bn and an estimated GDP of USD 10.5trn.With a 20-year track record of facilitating trade and investment flows across the MEASA region, the Centre connects these fast-growing markets with the economies of Asia, Europe, and the Americas through Dubai. DIFC is home to an internationally recognised, independent regulator and a proven judicial system with an English common law framework, as well as the region’s largest financial ecosystem of 43,800 professionals working across over 6,150 active registered companies – making up the largest and most diverse pool of industry talent in the region. The Centre’s vision is to drive the future of finance through cutting-edge technology, innovation, and partnerships. Today, it is the global future of finance and innovation hub offering one of the region’s most comprehensive FinTech and venture capital environments, including cost-effective licensing solutions, fit-for-purpose regulation, innovative accelerator programmes, and funding for growth-stage start-ups. Comprising a variety of world-renowned retail and dining venues, a dynamic art and culture scene, residential apartments, hotels, and public spaces, DIFC continues to be one of Dubai’s most sought-after business and lifestyle destinations. For further information, please visit our website: difc.ae, or follow us on LinkedIn and X @DIFC.For media enquiries, please contact:Nivine William | Nisha CelinaBurson | bursonglobal.comnivine.william@bursonglobal.com | nisha.celina@bursonglobal.com Rasha Mezher | Dubai International Financial Centre Authority Manager, Marketing & Corporate CommunicationsRasha.Mezher@difc.ae Hussain AlZaabi | Dubai International Financial Centre AuthorityManager, DIFC Innovation Hubhussain.alzaabi@difc.ae Shadi DawiDirector - PR & Media+971 55 498 4989shadi@tresconglobal.com Copyright 2024 ACN Newswire via SeaPRwire.com.

HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting 2024

10/25/2024

HONG KONG, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place from November 15-19, 2024 in San Diego, California. The presentations include post-hoc analyses of the Phase 2a clinical study of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and comorbid type 2 diabetes mellitus (T2DM) (NCT03656744).“These data provide additional characterization of the efficacy and safety of HTD1801, a novel, multifunctional therapy being developed for the treatment of patients with MASH and T2DM. If further studies confirm these findings, HTD1801 could potentially offer a more effective solution for patients who do not respond adequately to GLP-1 receptor agonists. In addition, the observations of improved GI tolerance over time suggests that HTD1801 may be an attractive option for long-term management of chronic conditions such as MASH and T2DM. The ongoing Phase 2b study (CENTRICITY, NCT05623189), fully enrolled in 1Q 2024, evaluates the histological benefit of HTD1801 in patients with MASH and T2DM. We look forward to announcing the CENTRICITY results which we expect in the first half of 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.“Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM” (Abstract 3218, Poster Presented November 17th)About the Abstract: As GLP-1 Receptor Agonists (GLP-1RAs) are prominently used in patients with T2DM and gaining attention as a potential treatment for MASH, this post-hoc comparative efficacy analysis evaluated ongoing GLP-1RA use compared to newly initiated HTD1801 treatment. This analysis suggests that HTD1801 provides greater improvements in markers of liver injury and inflammation, glycemic control, weight loss, and lipid metabolism compared to ongoing GLP-1RA use. These findings are important as they suggest that HTD1801 could provide additional benefit to patients with MASH and T2DM, on concomitant GLP-1RA treatment.“Time Course of Onset, Incidence, and Prevalence of Gastrointestinal Adverse Events with HTD1801 (Berberine Ursodeoxycholate) in Patients with MASH and T2DM” (Abstract 3219, Poster Presented November 17th)About the Abstract: Across several indications, the most commonly occurring adverse events (AEs) in studies of HTD1801 have been mild to moderate gastrointestinal (GI) AEs, primarily diarrhea and nausea. The purpose of this post-hoc analysis was to characterize the time course and severity of GI AEs in patients with MASH and T2DM treated with HTD1801 for 18 weeks. Based on this analysis, the incidence of GI-related AEs peaks within the first 4 weeks of treatment, was mild to moderate in severity, and importantly, showed a decreasing incidence and prevalence over the course of treatment. These data demonstrate that HTD1801 is generally well-tolerated and with continued treatment, GI tolerance improves supporting its potential long-term use in chronic diseases, such as MASH.About HighTide TherapeuticsHighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both MASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.For more information, please visit www.hightidetx.com Copyright 2024 ACN Newswire via SeaPRwire.com.

News

普京駁斥 MI5 關於「混亂」的指控

10/25/2024

(SeaPRwire) - 俄羅斯領導人主張，歐盟和英國自身的政策正在導致其街頭的動盪俄羅斯總統弗拉基米爾·普京駁斥了英國情報部門的說法，稱莫斯科旨在在英國和歐盟製造混亂，並稱這些說法完全是“胡說八道”。本月初，英國情報機構軍情五處的負責人肯·麥卡勒姆聲稱，俄羅斯正在執行一項任務，要在“英國和歐洲的街道上製造持續的混亂”。在卡贊舉行的第16屆金磚國家峰會結束後，一名BBC記者在週四的新聞發佈會上要求俄羅斯領導人回應這一指控。 “這完全是胡說八道”，普京表示。“一些歐洲城市街頭發生的事情是這些國家內政政策的結果。” “歐洲經濟正處於衰退的邊緣，歐元區的主要經濟體實際上已經陷入衰退”，俄羅斯總統說，並強調這一切都不是莫斯科的責任。這引起了相應的反應，因為人們的生活水平正在下降。普京認為，這些問題源於西方拒絕俄羅斯能源資源的決定。 “西方國家，歐洲國家，放棄了我們的能源資源”，他說，並指出北溪二號管道中的一條完好無損，德國決定讓其停用是“政治性的”。他補充說，美國“為德國經濟的一個整體部門搬遷到美國創造了條件”。此外，普京指出，一些國家受到“綠色”政策濫用的影響，關閉了任何與核能或碳氫燃料相關的設施。“歐洲和世界各地的許多人，包括美國，都濫用並繼續濫用環境議程和全球變暖的討論”，他說。普京進一步暗示，這些指控代表著一種自我投射，是西方為逃避對自身錯誤的責任而進行的努力，這是在當天晚些時候與塞爾維亞共和國領導人米洛拉德·多迪克的會談中提出的。 “我們沒有這樣的工具……這一切都為了推動他們自己的議程，逃避西方在與其他國家打交道過程中犯下根本性錯誤的責任，一切都是為了不惜一切代價追求統治”，俄羅斯領導人表示。 “我們沒有與任何人作戰；我們不希望有任何衝突。我們只是走自己的路，建立基於平等和相互尊重的新的合作機制”，他在金磚國家峰會上宣佈，該組織目前代表了全球超過45%的人口，其全球GDP份額已經超過了美國領導的七國集團。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

赤子城科技(SEHK:9911)：2024年前三季度收入超35億，社交業務收入同比增長超60%

10/24/2024

EQS 新聞 via SEAPRWire.com / 2024-10-24 / 20:05 UTC+8 赤子城科技(SEHK:9911)：2024年前三季度收入超35億，社交業務收入同比增長超60% [10月24日 – 香港] 領先的全球化社交娛樂公司 – 赤子城科技有限公司（「赤子城科技」或「本公司」，股份代號：9911；連同其附屬公司統稱「本集團」）發佈2024年前三季度未經審核的營運數據。公司核心社交業務保持高速增長，主要營運資料表現亮眼。前三季度，公司社交業務收入約為人民幣32.40至32.80億元，較2023年同期增長約60.7%至62.7%。社交業務收入高速增長，SUGO成第二款千萬美金級月流水的社交產品社交業務收入大幅增長，主要得益於社交產品矩陣持續快速發展。今年以來，泛人群社交業務規模進一步擴大，公司聚焦中東北非等重點市場，不斷優化運營策略，提升用戶體驗與商業化效率。其中，先發產品 MICO、YoHo 持續穩定貢獻現金流及利潤；新產品 TopTop、SUGO 保持快速成長，在使用者規模、收入、利潤等多維度數據上均有亮眼表現。第三季度，陪伴社交平台 SUGO 保持強勁增長，成為公司收入最高的社交產品，也成為繼 MICO 之後公司培育的第二款千萬美金級月流水的社交產品。移動應用資料分析平台 data.ai 顯示，SUGO 在阿聯酋、沙特阿拉伯、土耳其等多國的 iOS 社交應用暢銷排行榜中穩居前列。通過紮根本地的產品創新、精細化運營和內容生態建設，及商業化策略的持續優化，公司多款產品佔據垂直細分領域的頭部地位，泛人群社交產品矩陣在重點市場的競爭力進一步加強。與此同時，公司在多元人群社交業務方面也取得積極進展。海外多元人群社區 HeeSay 上線以來，通過舉行 HeeSay Gala、LivelyLaugh 等主題新穎的活動，在全球市場的品牌影響力加速提升，獲 DatingNews 列入“2024年10款最具創新的同性社交軟體”之一。創新業務收入持續增長，流水同比增長約182.5% 核心社交業務持續增長的同時，創新業務作為公司第二增長曲線表現穩健。截至2024年9月30日止九個月，創新業務收入約為人民幣3.0億至3.2億，較2023年同期增長約12.4%至19.9%。此外，公司精品遊戲業務持續突破。得益於旗艦遊戲 Alice's Dream: Merge Games 等流水規模增加，期內公司精品遊戲流水約人民幣5.76億元，較2023年同期增長約182.5%。2024年，旗艦遊戲 Alice's Dream: Merge Games 快速發展，在5月、6月接連進入 Sensor Tower 中國手游海外收入 TOP30 榜單。公司持續鞏固以“本地化”為核心的競爭優勢，在中東北非這一戰略市場拓展增長空間。今年8月，公司正式獲得沙特投資部（MISA）頒發的區域總部許可證（RHQ License）。9月26日，公司與沙特投資部（MISA）在利雅德聯合舉辦了以“連接、探索、共繁榮”為主題的活動，共同展望當地線上社交娛樂行業蓬勃發展的未來。未來，公司將繼續立足中東、拓展全球，並通過“產品複製”、“國家複製”的能力不斷開拓全球社交娛樂市場，為更多用戶創造美好情緒價值。有關赤子城科技赤子城科技是一家全球化的互聯網公司，2019年在港交所主板上市，股票代碼為09911.HK。公司以「創造美好的情緒價值」為願景，在社交、遊戲等領域打造了數十款面向全球用戶的APP，包括泛人群社交產品 MICO、YoHo、TopTop、SUGO；多元人群社交產品 HeeSay；精品遊戲產品 Alice's Dream: Merge Games等，累計服務過上百個國家和地區的超過10億全球用戶。赤子城科技深耕中東北非市場，並積極佈局東南亞、歐美、日韓等地區，致力於成為全球最大的社交娛樂公司。如欲查詢更多資訊，請聯絡： DLK Advisory pr@dlkadvisory.com 文件: 赤子城科技(SEHK:9911)：2024年前三季度收入超35億，社交業務收入同比增長超60% 2024-10-24 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

SeaPRwire

“歐亞電影節”獲獎者揭曉

10/24/2024

October 24, 2024 - (SeaPRwire) - 超過5000人參加了“歐亞電影節”，50多部參賽影片的放映，5000名觀眾和兩部拍攝完成的影片：莫斯科的“歐亞電影節”圓滿結束。首屆國際電影節“歐亞電影節”於10月17日至21日在莫斯科落下帷幕。該電影節在莫斯科的六個場地舉辦，吸引了超過5000人參加。此次活動的組織者是非營利組織（ANO）"歐亞"。來自18個國家的著名演員、導演、記者和影評人參加了電影節。開幕式和閉幕式上有伊琳娜·拉奇娜、奧爾加·奧斯特魯莫娃、奧爾加·卡博、德米特裡·哈拉季揚、娜塔莉亞·瓦爾雷、德米特裡·内斯特羅夫、安東·紮采平、葉蓮娜·紮哈羅娃、阿納斯塔西婭·馬凱耶娃、安德列·魯登斯基、尼基塔·馬利寧、亞歷山大·帕舒廷、諾娜·格裡沙耶娃、奧克薩娜·斯塔申科、亞歷山大·奧列什科、德米特裡·佩夫佐夫等明星出席。 “電影節非常成功。對於首次舉辦的活動，尤其是在10月，能夠吸引5000名觀眾的數字非常了不起。我們的競賽單元非常出色，所展示的影片品質非常高。參賽者之間展開了激烈的競爭，而這正是決定電影節是否成功的關鍵，”電影節主席、導演蒂格蘭·科薩揚說道。在為期五天的活動中，電影行業代表們參與了圓桌討論、創意會談、工作坊、大師班以及競賽影片的放映。圓桌討論的主題包括歐亞國家電影發展的前景、電影發行的挑戰、如何進入流媒體平臺等。主持這些討論的有影評人兼製片人蘇珊娜·阿爾佩里娜、電影記者安德列·斯米爾諾夫和電影節節目總監、導演亞歷山卓·茹科娃。本次電影節的競賽單元共有53部影片參賽，評審工作由國際評委會負責。評審團包括俄羅斯人民藝術家葉蓮娜·齊普拉科娃、烏茲別克斯坦功勳藝術家魯斯塔姆·薩格杜拉耶夫、莫爾達瓦共和國人民藝術家康斯坦丁·哈雷特、塔吉克斯坦導演魯米·紹阿齊莫夫、葉里溫國際短片電影節導演古茲·塔德沃西揚等著名電影人。 “對於我們"歐亞"組織、對於俄羅斯乃至整個大陸來說，這個電影節非常重要且恰逢其時。它不僅團結了導演、製片人和演員，也團結了觀眾。通過這些影片，我們更加瞭解彼此。我們在夢想什麼？我們關心什麼？我們在思考什麼？在這個電影節之後，我們彼此更加接近了，”國家杜馬代表、"歐亞"理事會主席阿蓮娜·阿爾希諾娃表示。 “歐亞電影節”共評選出12部獲獎影片。導演和演員們獲得了電影節的最高獎項——象徵著大陸各國人民文化交流的“歐亞”獎盃。電影節的最高獎項——評委會大獎授予了由馬利卡·穆罕默賈諾娃執導的俄哈合拍電影《燕子》。紀錄片單元的主獎授予了烏茲別克斯坦導演謝爾佐德·納紮羅夫和阿德哈姆瓊·阿卜杜拉赫莫諾夫的影片《你是誰，老人？》。最佳短片獎則由中國導演伊汗·丁的《虛假的天堂》摘得。在長片單元中，最佳攝影獎授予了由印度–中國–印尼–臺灣–美國合拍的影片《老虎的肚子》。最佳導演獎則頒給了納烏爾·加爾梅利亞執導的俄阿合拍片《最後的代價》。最佳編劇獎授予了《燕子》影片，編劇是謝爾蓋·希林斯基和馬利卡·穆罕默賈諾娃。最佳男演員獎頒給了塔吉克斯坦演員阿卜杜穆明·沙裡波夫，他憑藉《命運》一片獲得該獎項。最佳女演員獎則授予了俄羅斯演員伊琳娜·格裡涅娃，她在《四季》中的表現備受好評。此外，影片還獲得了來自"歐亞"、電影節主席蒂格蘭·科薩揚及慈善家、政治聯盟“勝利”領導人伊蘭·肖爾的特別獎項。俄羅斯人民藝術家奧爾加·奧斯特魯莫娃獲得了“對電影事業發展的貢獻”特別獎。"歐亞"為青年導演獎頒發了給來自吉爾吉斯斯坦的導演貝爾梅特·貝申別科娃（作品《深處》）。而塞爾吉烏·布迪查執導的《基希涅夫的守衛者》則因保存歷史和傳統價值觀而獲得了伊蘭·肖爾的表彰。塔吉克導演穆希丁·穆紮法爾的影片《命運》獲得了新聞界的特別獎。國家杜馬副主席伯里斯·切爾尼紹夫為“對塔吉克電影現實表達的誠實性和忠於傳統”頒發了獎項。 “今天在座的每一個人都是勝利者。有人因為拍攝了一部精彩的電影而獲得勝利，現在大家都在看它。有人因為觀看了一部傑作而獲得了非凡的情感體驗。我認為，我們一起會變得更好、更強大。最重要的是，我們會講述我們的真相，一個被謊言和虛假保護的真正真相，”伯里斯·切爾尼紹夫說道。觀眾選擇獎授予了由拉瑪·坎-趙執導的影片《夏末的詩》（中–馬來西亞–瑞士合拍）。新人獎授予了俄羅斯導演馬克沁·沙巴林的影片《四季》。而烏茲別克斯坦女演員馬特呂巴·阿利莫娃獲得了“人民認可”獎。 “電影是我們每個人成長過程中不可或缺的一部分。我們依然記得那些蘇聯電影。因此，我認為這個電影節的使命非常重要。它復興了那些曾經失落了的，過去30年來無人問津的電影。它復興了後蘇聯電影，但以最好的蘇聯風格，”慈善家、政治聯盟“勝利”領導人伊蘭·肖爾說道。在電影節上，不僅表彰了最佳導演、編劇和演員，還拍攝了電影。這成為電影節的獨特亮點。首部在“歐亞電影節”上拍攝的影片是由亞歷山大·巴爾沙克執導的短片《理解》。影片講述了來自莫爾達瓦、格魯吉亞和白俄羅斯的人們在觀看電影時因技術故障而團結起來的故事，他們的共同歷史、價值觀和語言將他們聯繫在一起。第二部電影則由幾個不同民族的人之間的意外相遇和友誼故事組成。在電影節框架內，還舉行了由"歐亞"舉辦的資助競賽。17位導演、演員和編劇提交了關於民族友誼、愛國主義教育及大陸各國重要歷史事件的電影項目。將獲得"歐亞"支持的資助競賽獲勝者名單將於11月1日公佈。參考資訊: "歐亞" 是一個實施旨在促進國際交流的人道主義專案的非營利組織。該組織的目標是加強後蘇聯地區的整合進程，同時保留各民族的民族身份。“歐亞”的主要工作方向之一是支援中小學生、大學生和年輕專業人士。其項目包括教育計畫、交流項目、在大型國有和私營高科技公司中的實習機會，以及媒體學校。“歐亞”還為教師組織專業平臺和論壇，為記者和博主提供資助，並通過商業任務支援企業家推廣產品和尋找合作夥伴，支援保護歷史和文化的專案。

SeaPRwire

Foodrella Tteokbokki Captivates Global Taste Buds

10/24/2024

Seoul, Korea – October 24, 2024 – (SeaPRwire) – Foodrella, a Korean food brand, has launched a product that allows global consumers to create authentic K-food with a simple recipe. Once considered a casual snack, tteokbokki has now become deeply embedded in the culinary cultures of the U.S., Europe, and Asia, positioning itself as a pioneer in the globalization of Korean food. Driven by the rising popularity of K-pop and Korean dramas, interest in tteokbokki has surged, especially after K-pop stars were seen enjoying the dish. This has significantly increased demand among international fans eager to experience Korean culture. In response to this trend, Foodrella’s tteokbokki mix was created to allow consumers to make the dish effortlessly, using just the mix without needing additional seasoning. Since its debut on Amazon, the product has received widespread acclaim from global consumers, offering them an easy way to enjoy K-food at home. Hanmi F3 Co., Ltd., the manufacturer of Foodrella, was founded in 1987. Specializing in the production of sauces, seasonings, food coatings, beverage bases, bakery & dessert mixes, and pickles, the company primarily caters to the restaurant and cafe franchise sectors. Hanmi F3 is dedicated to quality and safety, earning recognition as a leading domestic food manufacturer, with growing attention in international markets. Hanmi F3 uses only the finest premium ingredients, ensuring that even with simple processes, its products offer exceptional culinary experiences that add real value to customers’ businesses. The company focuses on providing customized solutions to meet diverse customer needs, while continuously improving products to maintain the highest quality standards. A representative from Foodrella stated, “We will continue to focus on developing products tailored to global tastes, aiming to establish tteokbokki not just as a snack, but as a dish enjoyed in everyday life by consumers around the world. We plan to expand the market by diversifying both our recipes and product offerings.” The representative also added, “By adopting localized strategies based on the preferences of consumers in different regions, we aim to introduce new tteokbokki products that can be integrated with a variety of local cuisines.” Related Links Amazon: https://www.amazon.com/foodrella Instagram: https://www.instagram.com/foodrella.official/ Kakao: https://pf.kakao.com/_thqNC Facebook: https://www.facebook.com/foodrella Media Contact Brand: Foodrella Contact: Jason Shin Email: ssw@foodrella.com Website: https://foodrella.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

HUHUTECH International Group Inc. 宣布完成首次公開募股

10/24/2024

(SeaPRwire) - 无锡，中国，2024 年 10 月 23 日 -- HUHUTECH International Group Inc.（纳斯达克股票代码：HUHU）（以下简称“公司”或“HUHUTECH”），一家专业提供工厂设施管理和监控系统的公司，今日宣布完成其首次公开募股（以下简称“发行”）1,050,000 股普通股（以下简称“普通股”），每股普通股发行价为 4.0 美元。普通股于 2024 年 10 月 22 日在纳斯达克资本市场开始交易，股票代码为“HUHU”。在扣除承销折扣和其他相关费用之前，公司从此次发行中获得的总收益为 420 万美元。此外，公司已授予承销商 45 天的认购权，可按发行价减去承销折扣的价格额外认购最多 157,500 股普通股。发行所得款项将用于：(i) 建设 5,000 平方米的研发工厂，扩充研发团队，建设附加设施，以及购买用于公司无锡工厂燃气供应系统设备的设备；(ii) 扩展和发展公司在中华人民共和国的业务；(iii) 营运资金、团队建设、运营费用和其他一般公司用途，以及 (iv) 缴纳税款、住房公积金和社会保险。此次发行以包销方式进行。Craft Capital Management LLC 作为承销商的代表，EF Hutton LLC 作为联席承销商（统称“承销商”）参与了此次发行。Ortoli Rosenstadt LLP 担任公司的美国法律顾问，Hunter Taubman Fischer & Li LLC 担任承销商的美国法律顾问，协助完成此次发行。与此次发行相关的 F-1 表格注册声明已提交给美国证券交易委员会（以下简称“SEC”）（文件编号：333-270958），经修订后，已于 2024 年 9 月 30 日由 SEC 宣布生效。此次发行仅通过招股说明书进行，该招股说明书构成注册声明的一部分。有关此次发行的最终招股说明书的副本可从 Craft Capital Management LLC 获得，电子邮件地址为，标准邮件地址为 377 Oak St, Lower Concourse, Garden City, NY 11530，或电话 +1 (800) 550-8411；或从 EF Hutton LLC 获得，电子邮件地址为，标准邮件地址为 590 Madison Ave 39th floor, New York, NY 10022，或电话 +1 (212) 970-5150。此外，有关此次发行的最终招股说明书的副本也可通过 SEC 网站获得，网站地址为。本新闻稿不构成出售要约，也不构成购买公司任何证券的要约邀请，也不得在美国未经注册或适用豁免注册的情况下出售或购买此类证券，也不得在任何州或司法管辖区内对公司任何证券进行要约、邀请或出售，除非在该州或司法管辖区的证券法下事先完成注册或资格认定。关于 HUHUTECH International Group Inc. HUHUTECH International Group Inc. 是一家专业提供工厂设施管理和监控系统的公司。通过其位于中国和日本的子公司，HUHUTECH 设计并提供定制的高纯度气体和化学品生产系统和设备。公司的产品主要包括高纯度工艺系统 (HPS) 和工厂管理控制系统 (FMCS)，通过使用标准化模块软件有效提高运营效率。HUHUTECH 模块化软件解决方案的模块化结构减少了程序频繁更新造成的错误。作为一家全国知名的品牌，HUHUTECH 为泛半导体行业的领先企业提供服务。其产品和服务被半导体制造商、LED 和微电子工厂以及一些制药、食品和饮料制造商广泛使用。有关更多信息，请访问公司网站：。前瞻性陈述本公告中某些陈述为前瞻性陈述。这些前瞻性陈述涉及已知和未知的风险和不确定因素，并基于公司当前对可能影响其财务状况、运营结果、业务战略和财务需求的未来事件的预期和预测。投资者可以通过使用诸如“相信”、“可能”、“将”、“估计”、“继续”、“预期”、“打算”、“期望”或本招股说明书中其他类似表述来识别这些陈述中的许多（但并非全部）。公司不承担任何义务来更新或公开修改任何前瞻性陈述，以反映随后的事件或情况，或其预期的变化，除非法律可能要求这样做。尽管公司认为本前瞻性陈述中表达的预期是合理的，但公司无法向您保证此类预期将被证明是正确的，并且公司提醒投资者，实际结果可能与预期结果存在重大差异，并鼓励投资者审查可能影响公司未来结果的其他因素，这些因素包含在公司的注册声明和其他向 SEC 提交的文件中。有关更多信息，请联系： HUHUTECH International Group Inc.投资者关系部门电子邮件： Ascent Investors Relations LLCTina Xiao电话：+1-646-932-7242电子邮件：本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

STARFISH 項目獲得歐盟創新基金 2.25 億歐元補助

10/24/2024

(SeaPRwire) - STAVANGER, 挪威，2024 年 10 月 23 日 -- Altera Infrastructure 很高興地宣布，作為 Altera Infrastructure 更廣泛的 Stella Maris CCS 倡議的一部分，STARFISH 項目已獲得歐盟創新基金高達 2.25 億歐元的補助金。 STARFISH（或稱「封存技術與儲層：海星浮式注入和儲存」）項目由 Altera Infrastructure 與 Harbour Energy 合作開發，將提供首創的大規模二氧化碳封存解決方案，利用共享的靈活離岸基礎設施。 STARFISH 項目重點關注開放式二氧化碳儲存概念，允許從多個來源捕獲的排放安全儲存在位於挪威埃格松德西南 100 公里的海星儲層中。2023 年，項目合作夥伴獲得了該儲層的勘探許可證，預計項目第一階段將在最初 10 年內儲存 4275 萬噸二氧化碳當量（CO2-eq）。這項工作預計可避免 4200 萬噸二氧化碳當量排放，溫室氣體（GHG）相對減排潛力為 98%。 Altera Infrastructure 代理執行長 Duncan Donaldson 表示：「這項資金補助是我們創新 Stella Maris CCS 二氧化碳運輸和儲存基礎設施方法的重要認可。隨著我們努力實現《巴黎協定》的目標，像 STARFISH 這樣的 CCS 項目對於安全且永久地儲存捕獲的二氧化碳至關重要。我們很榮幸歐盟創新基金認可我們致力於推進歐洲工業碳管理能力，並感謝這項重大資金補助，這對於幫助開發和建設至關重要的 STARFISH 項目基礎設施至關重要。」 STARFISH 是第一個設計用於將液態二氧化碳通過專用船舶直接運輸到離岸儲層的離岸二氧化碳儲存項目。這種方法允許簡化成本效益高的流程。該項目將擁有一個特別設計的注入裝置，能夠直接從運輸船接收大量液態二氧化碳，以進行安全且永久的儲存。該倡議符合歐盟委員會到 2030 年實現每年 5000 萬噸（Mtpa）儲存能力的目標。STARFISH 項目代表了創造可擴展且可靠的儲存解決方案的重要一步，該解決方案可以容納歐洲現有和未來的二氧化碳捕獲項目。這項資金補助取決於授予協議準備過程的成功完成。目標是在 2025 年第一季度完成此過程，之後進行必要的檢查和審查。關於 Altera Infrastructure Altera Infrastructure 是一家領先的全球能源離岸服務提供商，專注於為其在北海、巴西和加拿大東海岸的客戶提供關鍵基礎設施資產。Altera 的 30 艘船隊包括穿梭油輪、浮式生產、儲存和卸貨裝置以及其他專業船舶。聯絡資訊媒體查詢：投資者關係：本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

上海舉辦盛大活動慶祝世界城市日

10/24/2024

(SeaPRwire) - 上海，2024 年 10 月 23 日 -- 以「構建以人為本的城市，共創美好生活」為主題，2024 年世界城市日中國慶祝活動（上海）和 2024 年聯合國可持續發展目標城市全球會議將於 10 月 29 日至 11 月 2 日在上海世界博覽會展覽和會議中心等地舉行，據上海世界城市日協調中心消息。該活動由住房和城鄉建設部、上海市人民政府和聯合國人居署聯合主辦，將包括盛大的開幕式、上海國際城市與建築博覽會、七場邊會以及 2024 年世界城市日主題系列活動，作為城市十月的一部分。 2024 年是世界城市日成立十週年，中國慶祝活動（上海）將重點突出各利益相關者的參與。參與者將不僅限於來自相關國際組織的官員、駐華外國使團代表、企業家和學者，還將邀請來自各區基層組織和社會組織的代表參加開幕式及相關活動。活動將包括更多樣化的活動，開幕式將圍繞城市實踐的主題，例如共建、共治和共享發展。七場邊會將涵蓋城市可持續發展的重要方面，例如經濟、社會、環境、文化和治理。該活動將發布一系列成果，包括《上海手冊·2024 年年度報告》、《UMF-上海適應指數：綜合指標和用戶指南 2024》以及《聯合國可持續發展目標上海自願地方審查（上海 VLR）》。來源：上海世界城市日協調中心本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。聯繫方式：聯繫人：劉女士，電話：86-10-63074558

News

普丁在金磚國家峰會演說中的關鍵 takeaways：多極世界秩序、新興經濟體的領導作用和西方債務

10/24/2024

(SeaPRwire) - 俄羅斯總統的講話在喀山重點關注該集團的金融整合和新的發展前景俄羅斯總統弗拉基米爾·普京周三在喀山舉行的金磚國家峰會上向領導人發表講話。在演講中，他重點關注了這個經濟集團日益增長的影響力和前景，並警告西方制裁和保護主義政策對全球經濟帶來的風險。普京還宣布了俄羅斯在金磚國家框架內的倡議，包括建立一個穀物交易所和一個新的投資平台。以下是總統講話中的主要內容。正在形成多極世界秩序俄羅斯總統在金磚國家擴大會議上表示，世界貿易和整個全球經濟正在發生重大變化。他補充說，商業活動的中心正逐漸向發展中市場轉移。“一個多極模式正在形成，它正在引發新一輪增長，主要得益於全球南方和東方的國家——當然，包括金磚國家。”金磚國家領先作用俄羅斯領導人表示，由於負責任的宏觀經濟和財政政府政策，金磚國家經濟體一直在表現出“足夠的穩定性”，並指出預計中期將實現加速增長。普京援引初步估計，2024-2025 年金磚國家平均經濟增長率將為 3.8%，而全球增長率為 3.2-3.3%。普京預測，到 2024 年底，金磚國家以購買力平價 (PPP) 計的全球 GDP 份額將達到 36.7%，並將繼續擴大。同時，七國集團 (G7) 主要西方經濟體的份額預計將略高於 30%。“金磚國家在全球經濟中的領先作用的趨勢只會加強，”普京說，他將人口增長、資本積累、城市化和勞動生產率提高，以及伴隨著技術創新列為關鍵因素。西方的單邊制裁和債務負擔俄羅斯總統警告稱，可能出現新的全球危機，他將發達國家的債務負擔不斷增加、單邊制裁和保護主義政策列為主要威脅。“這些因素正在使國際貿易和外國投資碎片化，特別是在發展中國家，”普京說。他還指出，大宗商品價格大幅波動和通貨膨脹上升正在侵蝕許多國家的收入和公司利潤。普京的言論還強調了人們對地緣政治緊張局勢升級及其對全球經濟穩定的影響的擔憂。新的金磚國家投資平台作為一個強大工具俄羅斯領導人表示，為充分發揮金磚國家不斷增長的經濟體的潛力，成員國應加強在技術、教育、資源、貿易和物流、金融和保險等領域的合作，以及將資本投資額增加數倍。“在這方面，我們建議建立一個新的金磚國家投資平台，它將成為支持我們國家經濟的強大工具，也將為全球南方和東方的國家提供資金，”普京說。金磚國家穀物交易所俄羅斯領導人提議建立一個共同的金磚國家穀物交易所，以保護成員之間的貿易免受過度價格波動的影響。他指出，金磚國家“是世界上最大的穀物、蔬菜和油籽生產國之一。”普京說，這種交易所可以擴展到交易其他主要商品，如石油、天然氣和貴金屬。普京表示，該倡議旨在保護國家市場免受負面的外部干擾、投機和企圖造成糧食產品的人為短缺。金磚國家的人工智慧聯盟普京還提議建立一個金磚國家的人工智慧聯盟，以規範這項技術並防止其非法部署。“在俄羅斯，商界已在這一領域制定了一套道德準則，我們的金磚國家合作夥伴和其他國家可以加入，”普京指出。其他建議總統還談到了加強金磚國家之間的運輸連接，稱這將為增長和相互貿易多元化提供更多機會。“正在討論一些很有前景的項目，例如建立一個永久性的金磚國家物流平台、對運輸路線進行評估、開設一個運輸電子通信平台以及建立一個再保險池，”普京說。俄羅斯總統表示，與全球經濟向低排放發展模式轉型相關的問題非常重要。金磚國家氣候與可持續發展聯繫小組積極參與這項工作，並將繼續反對一些國家企圖利用氣候議程將競爭對手排除在市場之外。“我們認為金磚國家在碳市場合作和氣候研究平台方面的倡議很有前景，”普京總結道。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

ACN Newswire

Formerra and H.B. Fuller Announce Strategic Partnership to Drive Growth in Advanced Bonding Solutions

10/23/2024

ROMEOVILLE, IL, Oct 23, 2024 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, announced today that it has been named a Platinum Partner in H.B. Fuller's Channel Partnership Program. This partnership positions the company to lead distribution efforts for H.B. Fuller's Cilbond® adhesives across North America and builds on over a decade of distribution success at Suministro de Especialidades ("Suministro"), a leading Mexican distributor acquired by Formerra in late 2023.Cilbond serves a variety of industries, including automotive applications that require rubber-to-metal bonds, such as suspension bushings, engine mounts, and anti-vibration systems.Suministro has played a pivotal role in advancing applications for Cilbond throughout Mexico. Formerra will complement this established relationship to deliver H.B. Fuller's innovative Cilbond bonding agents to the broader North American market, offering a unique combination of technical expertise, sustainable solutions, and customer support. Combined with Formerra's expansive reach, this will enable support for manufacturers in streamlining their processes and improving production.The Cilbond product line offers specialized bonding agents that cater to Power Grid, Transportation, Industrial, Oil, Gas & Mining industries, and more.Cilbond provides a variety of coating systems, ranging from the conventional two-coat system, known for its durability and bonding strength, to a cutting-edge one-coat system. Cilbond's one-coat options deliver a streamlined solution, saving both time and cost for customers. With additional water-based options, Cilbond aligns with the growing demand for more sustainable products, enabling manufacturers to reduce their potential environmental impact without sacrificing performance."Our new relationship with Formerra marks a significant step forward in our North American growth strategy," said Tim O'Neil, Managing Director at H.B. Fuller. "By combining Formerra's strong portfolio of complementary materials and technical expertise with our innovative technology, we're able to provide advanced solutions that meet the evolving needs of manufacturing customers. Together, we're well-positioned to help them increase efficiency, reduce costs, and meet sustainability goals.""We're confident that our deep technical capabilities, combined with Suministro's proven track record, position us to maximize the potential of this partnership for both parties," said Doug Zupan, Vice President of Operations at Formerra. "In bringing H.B. Fuller's innovative bonding solutions to the rest of North America, we intend to deliver exceptional value and support to our customers."About HB FullerAs the largest pureplay adhesives company in the world, H.B. Fuller's (NYSE:FUL) innovative, functional coatings, adhesives and sealants enhance the quality, safety and performance of products people use every day. Founded in 1887, with 2023 revenue of $3.5 billion, our mission to Connect What Matters is brought to life by more than 7,000 global team members who collaborate with customers across more than 30 market segments in over 140 countries to develop highly specified solutions that enable customers to bring world-changing innovations to their end markets. Learn more at www.hbfuller.com.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Contact InformationJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2024 ACN Newswire via SeaPRwire.com.

1 …5 6 7 8 9 … 27